NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $3,096,000 | -14.2% | 180,438 | 0.0% | 0.10% | -18.5% |
Q1 2021 | $3,609,000 | +17.7% | 180,438 | 0.0% | 0.12% | +14.8% |
Q4 2020 | $3,067,000 | -29.7% | 180,438 | -31.4% | 0.11% | -34.1% |
Q3 2020 | $4,364,000 | -28.4% | 263,079 | 0.0% | 0.16% | -29.3% |
Q2 2020 | $6,093,000 | +29.7% | 263,079 | 0.0% | 0.23% | +9.4% |
Q1 2020 | $4,696,000 | -23.3% | 263,079 | -7.3% | 0.21% | -8.6% |
Q4 2019 | $6,123,000 | +18.5% | 283,679 | 0.0% | 0.23% | +3.1% |
Q3 2019 | $5,167,000 | -48.8% | 283,679 | 0.0% | 0.22% | -45.4% |
Q2 2019 | $10,093,000 | +5.9% | 283,679 | 0.0% | 0.41% | +6.5% |
Q1 2019 | $9,532,000 | +207.3% | 283,679 | +200.6% | 0.39% | +191.0% |
Q4 2018 | $3,102,000 | -76.1% | 94,384 | -55.6% | 0.13% | -71.7% |
Q3 2018 | $12,952,000 | +40.5% | 212,469 | +12.6% | 0.47% | +34.3% |
Q2 2018 | $9,218,000 | -30.3% | 188,769 | +51.6% | 0.35% | -32.0% |
Q1 2018 | $13,231,000 | +63.7% | 124,517 | -81.4% | 0.52% | +36.2% |
Q3 2014 | $8,082,000 | – | 669,600 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVEY CAPITAL MANAGEMENT INC | 598,400 | $10,083,000 | 3.98% |
Opus Point Partners Management, LLC | 348,583 | $5,874,000 | 3.88% |
Camber Capital Management LP | 3,500,000 | $58,975,000 | 3.81% |
1492 Capital Management LLC | 180,601 | $3,043,000 | 2.21% |
Virtus ETF Advisers LLC | 38,260 | $645,000 | 1.77% |
Cormorant Asset Management, LP | 765,156 | $12,893,000 | 1.54% |
Rhenman & Partners Asset Management AB | 581,000 | $9,790,000 | 1.48% |
Granahan Investment Management | 2,082,155 | $35,084,000 | 1.21% |
BRIDGER MANAGEMENT, LLC | 1,563,862 | $26,351,000 | 0.87% |
RICE HALL JAMES & ASSOCIATES, LLC | 899,531 | $15,157,000 | 0.87% |